004720.KO PharmGen Science Inc
- Market cap
- KRW 65.3B
- P/E
- 550.2x
- P/B
- 0.46x
- ROE
- -20.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 004720.KO undervalued?
Graham numberThe Graham number of PharmGen Science Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PharmGen Science Inc fundamental analysis
No fundamental analysis for PharmGen Science Inc yet.
PharmGen Science Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1966 and…
Full company profilePharmGen Science Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PharmGen Science Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 71.5B | 79.9B | 89.1B | 95.1B | 96.6B | 110B | 151B | 167B | 171B | 173B | 182B |
| Gross Profit | 40.0B | 41.3B | 46.2B | 50.4B | 53.6B | 60.8B | 81.3B | 97.9B | 108B | 112B | 120B |
| Operating Income | 4.84B | 6.01B | 4.99B | 1.20B | -450M | -4.94B | 7.48B | 9.13B | 10.6B | 5.99B | 7.13B |
| EBITDA | - | 7.33B | 5.37B | 4.20B | 14.5B | 46.8B | 96.8B | 17.0B | 9.81B | -145B | 11.9B |
| Net Income | 3.45B | 4.32B | 4.47B | 302M | 9.22B | 32.5B | 70.1B | 6.09B | 2.79B | -117B | -29.1B |
| EPS | - | 384 | 388 | 26 | 629 | 2,213 | 4,437 | 339 | 154 | -5,323 | -1,330 |
| Balance Sheet | |||||||||||
| Total Assets | 64.3B | 68.5B | 98.2B | 100B | 136B | 220B | 317B | 336B | 363B | 195B | 184B |
| Total Liabilities | 27.9B | 17.4B | 41.3B | 43.8B | 52.0B | 93.4B | 110B | 108B | 114B | 49.1B | 44.2B |
| Shareholders' Equity | 36.4B | 51.0B | 56.7B | 56.1B | 83.5B | 127B | 207B | 228B | 249B | 146B | 140B |
| Cash & Short-term Investments | 5.43B | 5.18B | 22.4B | 11.4B | 25.9B | 33.7B | 19.4B | 36.9B | 37.9B | 21.9B | 19.5B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.75B | 1.84B | 4.22B | 2.52B | 2.68B | 7.78B | -1.29B | 5.44B | 2.38B | 5.32B | 13.4B |
| Capital Expenditure | 3.43B | 1.54B | 892M | 6.16B | 4.34B | 30.7B | 12.0B | 3.29B | 2.78B | 2.67B | 4.77B |
| Free Cash Flow | - | 130M | 3.24B | -4.26B | -2.79B | -26.2B | -13.2B | 2.15B | -399M | 2.65B | 8.68B |
| Ratios | |||||||||||
| ROE | 9.5% | 8.5% | 7.9% | 0.5% | 11.0% | 25.6% | 33.8% | 2.7% | 1.1% | -79.7% | -20.8% |
| ROA | 5.4% | 6.3% | 4.6% | 0.3% | 6.8% | 14.7% | 22.1% | 1.8% | 0.8% | -59.7% | -15.8% |
| Net Profit Margin | 4.8% | 5.4% | 5.0% | 0.3% | 9.5% | 29.6% | 46.4% | 3.7% | 1.6% | -67.4% | -16.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PharmGen Science Inc dividends
PharmGen Science Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Dec 9, 2014.
Who owns PharmGen Science Inc
- Insiders 23.10%
- Institutions 0.68%
- Public & others 76.22%
- Shares outstanding 22.6M
- Free float 13.5M
PharmGen Science Inc company profile
- Company name
- PharmGen Science Inc
- Ticker
- 004720.KO
- ISIN
- KR7004720009
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 226
- Fiscal year end
- December
- Address
- 50, Jeyakgongdan 2-gil, Hwaseong-si, South Korea, 18622
- Phone
- 82 2 2194 3532
- Website
- wooridulpharm.com
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1966 and is headquartered in Hwaseong-si, South Korea.
PharmGen Science Inc management
2- Mr. Hee-Deok ParkCEO & Director · born 1967
- Ms. Hye-Youn KimChief Executive Officer